DG9-Conjugated Morpholino Rescues Phenotype in Spinal Muscular Atrophy Mice

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by reduced SMN1 gene expression.
• Current antisense oligonucleotide (ASO) therapies like nusinersen require invasive intrathecal injections and struggle with blood-brain barrier (BBB) penetration.
• High cost and administration challenges limit nusinersen's accessibility and therapeutic potential.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel DG9-conjugated phosphorodiamidate morpholino oligomer (DG9-PMO) for treating SMA.
• To assess DG9-PMO's ability to cross the BBB and distribute to the central nervous system (CNS) following subcutaneous administration.
• To compare DG9-PMO's therapeutic effects against existing treatments in a severe SMA mouse model.

Main Methods:

• Systemic administration of DG9-PMO in a severe SMA mouse model.
• Quantitative RT-PCR and western blotting to measure SMN2 expression.
• Histology and functional tests to assess motor function and neuromuscular junctions.
• ELISA for DG9-PMO quantification and toxicology analysis for safety evaluation.

Main Results:

• DG9-PMO demonstrated significant CNS distribution after subcutaneous injection.
• Treatment increased survival rates, improved motor coordination, and mitigated muscle pathology in SMA mice.
• DG9-PMO significantly enhanced full-length SMN2 expression in both CNS and systemic tissues.
• DG9-PMO showed comparable or superior efficacy to nusinersen and R6G-PMO.

Conclusions:

• DG9-PMO represents a promising advancement in ASO-based SMA therapy, overcoming BBB penetration and administration route limitations.
• This novel ASO conjugate offers potential for broader accessibility and improved therapeutic outcomes for SMA patients.
• Further development of DG9-PMO could significantly impact the management of spinal muscular atrophy.